✦ LIBER ✦

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

✍ Scribed by Paul G. Richardson; Pieter Sonneveld; Michael W. Schuster; Edward A. Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D. Cavenagh; Anthony L. Boral; Dixie-Lee Esseltine; Patrick Y. Wen; Anthony A. Amato; Kenneth C. Anderson; Jesus San Miguel

Book ID: 108676179
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 115 KB
Volume: 144
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2008.07573.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for, and reversibility of,

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

✍ Meletios A. Dimopoulos; Maria-Victoria Mateos; Paul G. Richardson; Rudolf Schlag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

The potential benefits of participating

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

✍ Paul G. Richardson; Jacob P. Laubach; Robert L. Schlossman; Irene M. Ghobrial; K 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

The relationship between quality of resp

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

✍ Ruben Niesvizky; Paul G. Richardson; S. Vincent Rajkumar; Morton Coleman; Laura 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB

Mechanisms of peripheral neuropathy asso

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

✍ Annemiek Broyl; Sophie L Corthals; Joost LM Jongen; Bronno van der Holt; Rowan K 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 125 KB

Bortezomib Plus Melphalan and Prednisone

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

✍ Mateos, M. V.; Richardson, P. G.; Schlag, R.; Khuageva, N. K.; Dimopoulos, M. A. 📂 Article 📅 2010 🏛 American Society of Clinical Oncology 🌐 English ⚖ 493 KB